Stocks · Healthcare · Biotechnology
Monopar Therapeutics Inc. MNPR
$78.29 +0.41% Close, Oct 5, 2026 · NASDAQ · Market cap $522.3M
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 22.1% in a year.
- The stock is in an uptrend: above its 200-day average for 75 trading days, with the 50-day average above the 200-day.
- The stock is 37% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 47%
- Accruals (lower is better)Bottom 1%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 38%
- Free-cash-flow yieldBottom 1%
- EBITDA / enterprise valueTop 49%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 48%
- 6-month returnTop 24%
- 1-year return vs S&P 500Bottom 29%
- Distance from 52-week highBottom 43%
- Trend checklist (0–4)Top 43%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 39%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 48%
- Upside to consensus price targetTop 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 47%
- Maximum drawdown, 3 yearsTop 45%
- Beta vs S&P 500 (lower is better)Top 44%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -16.9% | — | Top 47% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 2399.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -19.16%
- Shareholder yield
- -19.16%
- Share count change, 1 year
- +22.1%
- Share count change, 3-year CAGR
- -14.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +9.2%
- Average 2-day reaction, last 8
- +1.6%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $126.00
- Target vs current price
- +60.9%
- Analysts with a rating
- 14
- Share rating Buy or Strong Buy
- 79%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | +3.6% | +0.4% | +4.0% | -1.8% | — |
| May 14, 2026 | +56.6% | -0.7% | +5.7% | -3.8% | +89.4% |
| Mar 27, 2026 | -19.1% | -0.8% | +1.0% | -2.5% | +49.9% |
| Nov 13, 2025 | -4.3% | +5.4% | +0.5% | -6.7% | -30.9% |
| Aug 12, 2025 | +25.5% | +14.6% | +9.3% | +43.4% | +163.9% |
| May 13, 2025 | +41.5% | -3.6% | +5.1% | -1.7% | +14.2% |
| Mar 31, 2025 | -519.4% | -9.7% | -25.6% | +1.2% | -20.9% |
| Nov 8, 2024 | +19.6% | +7.3% | +15.9% | +36.7% | +199.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.62 | -$0.64 | +3.6% | — |
| May 14, 2026 | -$0.46 | -$1.06 | +56.6% | — |
| Mar 27, 2026 | -$0.61 | -$0.51 | -19.1% | — |
| Nov 13, 2025 | -$0.48 | -$0.46 | -4.3% | — |
| Aug 12, 2025 | -$0.35 | -$0.47 | +25.5% | — |
| May 13, 2025 | -$0.38 | -$0.65 | +41.5% | — |
| Mar 31, 2025 | -$2.23 | -$0.36 | -519.4% | — |
| Nov 8, 2024 | -$0.37 | -$0.46 | +19.6% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -623.44% | — | — | Bottom 1% |
| Earnings yield | -2.99% | — | — | Top 38% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 75
- 50-day average slope (20 days)
- -2.8%
- 200-day average slope (20 days)
- +1.8%
- Distance from 50-day average
- -26.5%
- Distance from 200-day average
- +2.3%
- RSI (14)
- 21.0
- Relative volume
- 0.87×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 57.2%
- Volatility vs own 5-year history
- 5th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.01
- Correlation with S&P 500
- 0.09
- Current drawdown from 1-year high
- -36.8%
- Maximum drawdown, 3 years
- -67.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 11, 2021 | Nov 20, 2023 | -97.3% | 698 days | 454 days (Sep 15, 2025) |
| Oct 13, 2025 | Apr 29, 2026 | -50.9% | 136 days | 48 days (Jul 9, 2026) |
| Aug 19, 2026 | Oct 1, 2026 | -37.0% | 30 days | Not yet recovered |
| Sep 30, 2020 | Nov 10, 2020 | -18.5% | 29 days | 20 days (Dec 9, 2020) |
| Dec 24, 2020 | Dec 31, 2020 | -18.3% | 4 days | 18 days (Jan 28, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $522.3M
- EPS, diluted (TTM)
- -$2.34
- Revenue (TTM)
- $0
- 52-week range
- $50.07 – $124.82
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$9.1M | -$10.5M | -$8.8M | -$16.2M | -$16.7M |
| Net income | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| EPS (diluted) | -$0.73 | -$0.83 | -$0.58 | -$1.36 | -$1.85 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.3M | -$10.9M | -$2.6M | -$2.5M | -$3.4M | -$5.2M | -$3.9M | -$5.3M |
| EPS (diluted) | -$0.11 | -$0.95 | -$0.38 | -$0.35 | -$0.48 | -$0.78 | -$0.46 | -$0.62 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Capital expenditure | $1 | $0 | $0 | $0 | $0 |
| Free cash flow | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $10.9M | $109,337 | $2.1M | $59.4M | $92.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $134.3M
- Total assets
- $135.0M
- Total liabilities
- $4.1M
- Total debt
- $107,829
- Net debt
- -$52.6M
- Shareholders’ equity
- $130.9M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 844,226
- Days to cover
- 7.20
- Change vs previous report
- -1.0%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Aug 13, 2024
- 1-for-5